Stereotactic body radiotherapy for oligometastatic renal cell carcinoma—are we ready to roll?

Approximately 1 in 4 patients with renal cell carcinoma (RCC) present with metastatic disease, with an additional 20–30% experiencing metastatic relapse after primary surgical therapy for localized disease (1). Despite the high rate of local and/or metastatic relapse, there are no randomized studies to guide therapy.